No insider purchase over the last 90 days. The latest was filed 10 Nov 2025.
Every trade that managers of OmniAb, Inc. disclose to SEC (Form 4) is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for OmniAb, Inc. logged 24 filings by 9 insiders.
Both sides are active: 1 purchase worth €44k and 3 sales worth €42k, from 1 insider and 3 insiders respectively. Taken together, the purchases exceed the sales by €1,951. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €44k, the purchase published on 10 November 2025 by Higgins John l is the largest of the period. On the buying side, the filings list 1 senior executive among the declarants.
Compared with its exchange (5,808 companies, median 19 filings), a count of 24 filings is above the norm. The full history, which starts in 2022, counts 21 purchases against 4 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 18.7 m USD and net income of -64.8 m USD.
The clock since the last published purchase (10 November 2025) now reads 342 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate OmniAb, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$8.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 131 declarations
OmniAb, Inc. is a company focused on the development of therapeutic antibodies. It is listed on the XNAS market.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 18.7 m USD | -64.8 m USD | -0.57 USD | 10-K |
| Dec 2024 | 26.4 m USD | -62.0 m USD | -0.61 USD | 10-K |
| Dec 2023 | 34.2 m USD | -50.6 m USD | -0.51 USD | 10-K |
| Dec 2022 | 59.1 m USD | -22.3 m USD | -0.26 USD | 10-K |
| Dec 2021 | 34.7 m USD | -27.0 m USD | -0.33 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.